Inotropic Stimulation Induces Cardiac Dysfunction in Transgenic Mice Expressing a Troponin T (I79N) Mutation Linked to Familial Hypertrophic Cardiomyopathy*

The cardiac troponin T (TnT) I79N mutation has been linked to familial hypertrophic cardiomyopathy and a high incidence of sudden death, despite causing little or no cardiac hypertrophy. In skinned fibers, I79N increased myofilamental calcium sensitivity (Miller, T., Szczesna, D., Housmans, P. R., Zhao, J., deFreitas, F., Gomes, A. V., Culbreath, L., McCue, J., Wang, Y., Xu, Y., Kerrick, W. G., and Potter, J. D. (2001) J. Biol. Chem. 276, 3743–3755). To further study the functional consequences of this mutation, we compared the cardiac performance of transgenic mice expressing either human TnT-I79N or human wild-type TnT. In isolated hearts, cardiac function was different depending on the Ca\(^{2+}\) concentration of the perfusate; systolic function was significantly increased in Tg-I79N hearts at 0.5 and 1 mmol/liter. At higher Ca\(^{2+}\) concentrations, systolic function was not different, but diastolic dysfunction became manifest as increased end-diastolic pressure and time to 90% relaxation. In vivo measurements by echocardiography and Doppler confirmed that base-line systolic function was significantly higher in Tg-I79N mice without evidence for diastolic dysfunction. Inotropic stimulation with isoproterenol resulted only in a modest contractile response but caused significant mortality in Tg-I79N mice. Doppler studies ruled out aortic outflow obstruction and were consistent with increased chamber stiffness. We conclude that in vivo, the increased myofilament Ca\(^{2+}\) sensitivity due to the I79N mutation enhances base-line contractility but leads to cardiac dysfunction during inotropic stimulation.

Mutations in cardiac troponin T (TnT)\(^{1}\) have been implicated in familial hypertrophic cardiomyopathy (FHC) (1–5). Individuals with cardiac TnT mutations appear to have a high incidence of sudden cardiac death at a young age, although heterozygote individuals have either little or no cardiac hypertrophy (1, 3, 4). At present, there is no clear understanding as to why TnT mutations in particular pose a high risk for sudden death, as opposed to, for example, mutations in the myosin heavy chain, which usually cause a much greater degree of cardiac hypertrophy. Sudden cardiac death of FHC patients is often caused by ventricular tachyarrhythmias (6), but its cause remains unknown for patients with TnT mutations. In fact, the clinical features of hypertrophic cardiomyopathy have been established mostly without knowledge of the genotype and may not apply to patients carrying specific TnT mutations. Given the paucity of clinical information, a transgenic mouse model provides the opportunity to study the functional consequences of a TnT mutation in an in vivo system.

To investigate the mechanisms of how a TnT mutation alters cardiac function and lead to sudden cardiac death, we have generated transgenic mice expressing the human cardiac TnT-I79N mutant (Tg-I79N). Similar to humans carrying this mutation, Tg-I79N mice show no cardiac hypertrophy (7). We found a large increase in Ca\(^{2+}\) sensitivity of the skinned cardiac fibers from Tg-I79N mice compared with fibers from transgenic mice expressing human wild-type TnT (Tg-WT), but maximal developed force was significantly lower in cardiac fibers from Tg-I79N mice (7).

In this study, we examined the effect of the I79N mutation on cardiac performance and electrophysiological properties of the whole heart, in vitro and in vivo. We found that the effect of the mutant protein was dependent on the inotropic state of the heart; under base-line conditions, systolic function was higher in Tg-I79N mice, with little effect on diastolic function. However, during inotropic stimulation with high extracellular Ca\(^{2+}\) or with isoproterenol, diastolic function was impaired, both in the isolated heart and in vivo. Based on these results, we conclude that the increased myofilament Ca\(^{2+}\) sensitivity due to the I79N mutation enhances base-line contractility but leads to cardiac dysfunction during inotropic stimulation. In humans carrying the TnT-I79N mutation, this mechanism may contribute to excess mortality during exercise or in pathophysiological states with high levels of endogenous catecholamines, even in the absence of significant cardiac hypertrophy.

EXPERIMENTAL PROCEDURES

Experimental Protocol—All studies were carried out according to National Institutes of Health guidelines and approved by the institutional animal care and use committee. To examine the effect of the I79N

---

* This work was supported by American Heart Association fellowship 9926387T1 and Pharmaceutical Research and Manufacturers of America Foundation Faculty Development Award (to B. C. K.), and National Institutes of Health Grants AR 45391 and 2R01 HL42325 (to J. D. P.), RO1 HL16152 (to M. M.), and RO1 GM63665 (to P. R. H.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Dept. of Molecular and Cellular Pharmacology, University of Miami School of Medicine, 1600 N.W. 10th Ave., Miami, FL 33136. Tel.: 305-243-5874; Fax: 305-243-6225; E-mail: jdpotter@miami.edu

\(^{1}\) The abbreviations used are: TnT, cardiac troponin T; FHC, familial hypertrophic cardiomyopathy; WT, wild type; EDP, end-diastolic pressure; LV, left ventricle; ECG, electrocardiogram; Tg, transgenic.
mutation on cardiac performance and electrophysiology, we compared 3–4-month-old mice: transgenic mice expressing either human wild-type (Tg-WT, line 3) or mutant cardiac TnT (Tg-I79N, lines 8 and 9) and nontransgenic littermates (non-Tg). The generation and *in vitro* characterization of this transgenic model has been described (7). All three transgenic lines had high expression levels of the transgenic protein, with 70, 52, and 34% replacement of endogenous mouse TnT (line 3, 8, and 9, respectively).

**Isolated Perfused Heart Preparation**—Mice were anesthetized with 20 ml/kg 2% tribromoethanol (Avertin) via intraperitoneal injection. After a surgical level of anesthesia was confirmed, a thoracotomy performed, the heart was rapidly excised, and perfused in the Langendorff mode as described previously for mouse hearts (8). In brief, the chest was opened, the heart was rapidly excised, and the aorta was cannulated. Retrograde perfusion via the aorta was carried out at a constant perfusion pressure of 68 mm Hg at 37 °C. The surgical level of anesthesia was confirmed, a thoracotomy performed, the heart was rapidly excised, and perfused in the Langendorff mode as described previously for mouse hearts (8). In brief, the chest was opened, the heart was rapidly excised, and the aorta was cannulated. Retrograde perfusion via the aorta was carried out at a constant perfusion pressure of 68 mm Hg at 37 °C. The heart rate, the atrioventricular node was ablated, and the hearts were epicardially paced at 420 min⁻¹ via a bipolar Ag-AgCl contact electrode placed on the base of the right ventricle.

Hearts were allowed to equilibrate for 15 min before base-line left ventricular pressure recordings were obtained. To examine the effects of different isotonic states, the heart was then perfused with KCl buffer containing free [Ca²⁺] of 0.5, 1, 2, 3, and 4 mM. Free [Ca²⁺] was calculated using Fabiato's program (9). Contractile measurements were obtained at the end of each 5 min at the respective [Ca²⁺]. All perfusion buffers were equilibrated with 95% O₂ plus 5% CO₂ for at least 1 h prior to the experiment, yielding a pH of 7.4.

**Measurement of Isovolumic Cardiac Performance**—A water-filled balloon custom-made of polyvinylchloride film was inserted through the mitral valve into the left ventricle via an incision in the left atrium as described (8). A 2.0-French microtip transducer (Millar, Inc, Texas) was guided through the polyethylene tube and positioned inside the balloon. The balloon was inflated to adjust the end-diastolic pressure (EDP) at 6–8 mm Hg, and the balloon volume was held constant for the duration of the experiment. The left ventricular pressure was digitized as 1000 samples/s with the use of a commercially available data acquisition system (PowerLab, ADInstruments, Inc.). The fast sampling rate coupled with the use of a pressure catheter with a flat frequency response up to 10 kHz allowed us to do the detailed kinetic analysis of the pressure recordings outlined below.

The following indices of cardiac performance were measured off-line using custom built software (National Instruments, Inc.) and averaged from three consecutive beats at base line and at the end of each Ca²⁺ concentration step: left ventricular systolic pressure, EDP, developed pressure (the difference between systolic pressure and EDP), the minimum and maximum values of the first derivative of left ventricular pressure (+dP/dt and −dP/dt), ratio of +dP/dt and −dP/dt, time to reach peak systolic pressure, time to reach peak +dP/dt, and time from peak systolic pressure to reach 90% relaxation. To determine the time constant of isovolumic pressure decay, the left ventricle (LV) pressure curve was fitted from the time of minimum dP/dt to a level 5 mm Hg above the EDP of the next beat using a monoexponential function as described (8).

**Surface Electrocardiogram (ECG) and Systolic Blood Pressure Measurements**—For the ECG measurements, mice were anesthetized either with ketamine (100 mg/kg) and xylazine (5 mg/kg) or with 20 ml/kg of 2% tribromoethanol (Avertin) via intraperitoneal injection. Mice were positioned prone in a shielded box, with all four extremities immersed in 3 M KCl-filled wells to reduce skin resistance. The bottom of the shielded box was heated to 37 °C using a circulating water bath to maintain a stable body temperature during the experiment. To accurately capture the ECG signals from mice, which have the high heart rates (500–600 beats) and a very short QRS duration, a custom-built ECG amplifier (Vibraspec, Bear Island, ME 04662) was used. This amplifier provided a high frequency response and large gain (1000 Hz and 10,000-fold gain) and was used to record bipolar limb leads in standard fashion as described (10). Signals were digitized at 1 kHz using National Instruments, Inc. data acquisition system with custom built software. For each animal, PR and QRS intervals were measured from three consecutive beats in leads I and II and averaged. For QT interval measurements, the recordings were signal-averaged over a 30-s time interval using the peak of the R-wave as the fiducial point as described (11). This procedure reduced the effect of respiratory and motion artifacts on QT measurements. The heart rate was measured as the average over the 30-s interval, and the QT interval was measured in the lead with the longest and most prominent T-wave.

Systolic blood pressure and heart rate were measured in conscious and anesthetized mice using a commercially available, noninvasive computerized tail-cuff system (BP-2000, Visitech, Apex, NC).

**Echocardiography and Doppler Measurements**—Mice were anesthetized as for the ECG measurements and positioned supine on a heated surface (37 °C) to maintain a stable body temperature during the experiment. Echocardiography and Doppler measurements were performed with a 1-cm gel standoff in a left lateral position similar to the technique used by Hoit et al. (12). An Acuson Sequoia C256 system with a linear transducer in 13-MHz mode was used to obtain high resolution two-dimensional and M-mode measurements. The two-dimensional guided M-mode of the LV was performed in short axis at the tip of the mitral leaflets and through the center of the LV cavity. The probe position was confirmed by rotating the probe 90° and obtaining two-dimensional guided long axis M-mode measurements in the same animal. Two-dimensional guided Doppler flow measurements of aortic outflow and mitral inflow were obtained. Mitral inflow velocities were recorded only after extensive scanning from multiple vantage points to
ensure that the maximal velocity was obtained. In most situations, this was an apical window that corresponds to an “off-axis” apical window (displaced toward the parasternal window). A limb-lead ECG was simultaneously recorded during echocardiography and stored both on computer, for off-line analysis, and on the echocardiogram videotape. The echo images were digitized from videotape and measurements performed using a digital image analysis package (Nova Microsonics/Eastman Kodak Co.). LV end-systolic and end-diastolic internal diameters (LVEDD and LVEF, respectively) and LV wall thickness were measured for each animal from the M-mode image. Aortic outflow velocity, aortic ejection time, aortic acceleration time to peak outflow, early and late mitral inflow velocity (E-wave and A-wave, respectively), and E-wave deceleration time were measured from the Doppler recordings in standard fashion, and the E to A ratio was calculated. To assess systolic function, LV shortening fraction (SF) was calculated. To assess diastolic function, and indexes of cardiac performance in the isolated perfused, isovolumically contracting heart. This experimental preparation permits exact control of the loading conditions and has been used to examine both systolic and diastolic function in other murine models (8, 17–19). Systolic function was assessed from systolic pressure, time to peak pressure, and maximum rate of pressure rise (+dP/dt). Diastolic function was assessed from the maximum rate of pressure decay (−dP/dt) and from time to 90% relaxation and the time constant of isovolumic relaxation. When hearts were paced at 420 min−1 and end-diastolic pressure was set at 6–8 mm Hg, systolic performance was not statistically different between Tg-I79N, Tg-WT, and non-Tg hearts (Table I). However, the initial rise of pressure was faster in Tg-I79N hearts (Fig. 1, arrow). Thus, time to maximum +dP/dt was significantly shorter in the Tg-I79N hearts (Table I). On the other hand, time to 90% relaxation and the relaxation time constant were significantly longer in the Tg-I79N hearts compared with both Tg-WT and non-Tg hearts (Table I).

pressure (p < 0.05). Taken together, these results indicate that Tg-I79N hearts had significantly impaired diastolic function.

Force traces were simulated as would be observed during isometric twitch contractions of Tg-WT and Tg-I79N ventricular myocardium using variables (off-rate of Ca2+ from troponin C and cross-bridge dissociation constant) derived previously (7). Transgenic I79N myocardium relaxed more slowly than non-Tg myocardium using variables (off-rate of Ca2+ from troponin C and cross-bridge dissociation constant) derived previously (7).
Cardiac Dysfunction of TnT (I79N) Transgenic Mice

FIG. 3. Echocardiography and Doppler measurements from Tg-WT and Tg-I79N (line 9) mice. A, representative examples of two-dimensional guided M-mode recordings obtained with a high resolution 13-MHz transducer. Tg-I79N mice demonstrate an increased LV shortening fraction at base line. arrows indicate LV end-diastolic and end-systolic dimensions. B, representative examples of two-dimensional guided Doppler recordings of aortic outflow velocity. Tg-I79N mice demonstrate a shorter acceleration time (equal to the time from opening of the aortic valve to peak flow velocity) at base line.

Tg-WT, which is consistent with the experimental observations in isovolumetrically beating heart.

**Ca**2+ Dependence of Cardiac Performance—We also examined the changes in cardiac performance in response to changes in [Ca**2+**]c (Fig. 2). At [Ca**2+**]c of 0.5 and 1 mM, developed pressure was significantly higher in Tg-I79N than in Tg-WT hearts (Fig. 2A). At higher [Ca**2+**]c, however, developed pressure was not significantly different between the two groups. Thus, there was a leftward shift of the [Ca**2+**]c-pressure relationship in Tg-I79N hearts. Indices of diastolic function demonstrated a different [Ca**2+**]c dependence; at [Ca**2+**]c of 0.5 and 1 mM, EDP was significantly lower in Tg-I79N hearts (Fig. 2B), while time to 90% relaxation was not significantly different from Tg-WT (Fig. 2C). At higher [Ca**2+**]c, EDP was significantly higher (Fig. 2B), and time to 90% relaxation was significantly longer in Tg-I79N hearts than in Tg-WT hearts (Fig. 2C). Therefore, Tg-I79N hearts demonstrate increased systolic performance at low [Ca**2+**]c, but performance comparable with that of Tg-WT at a [Ca**2+**]c of 2 mM or above. On the other hand, diastolic function is comparable with that of Tg-WT at low [Ca**2+**]c, but significantly impaired at high [Ca**2+**]c.

**In Vivo Cardiac Performance and Cardiac Electrophysiology of Tg Mice**

Base-line Echocardiography and Doppler Measurements—Echocardiography and Doppler measurements have been used extensively to characterize the cardiac phenotype of transgenic mouse models (21). We measured cardiac dimensions, indices of systolic function, and diastolic ventricular filling by two-dimensional guided M-mode (Fig. 3A) and Doppler (Fig. 3B). Table II summarizes the results. Indices of systolic contractile function (LV shortening fraction and VCFc) were significantly higher in both Tg-I79N lines compared with Tg-WT. Evidence for increased contractility was also present on flow measurements by Doppler. Tg-I79N mice had a significantly shorter time to peak outflow velocity (Fig. 3B). Base-line diastolic filling parameters measured by Doppler (E-wave, A-wave, E-wave deceleration time, E/A ratio) were not statistically different be-
between all four lines. Thus, unlike the isolated perfused heart, systolic function was increased in Tg-I79N mice, but diastolic function appeared to be normal. One reason for this apparent discrepancy may be related to the slow heart rates ($\approx 250 \text{ min}^{-1}$) induced by the ketamine/xylazine anesthesia. We therefore repeated the echocardiography and Doppler measurements using a different anesthetic, Avertin, which produces much less bradycardia. Since there were no large differences in the cardiac parameters between Tg-I79N lines 8 and 9, we compared Tg-I79N line 9 with Tg-WT mice and non-Tg mice. Heart rates indeed increased to a similar extent in all groups (Table II). Systolic function was significantly different between all three groups (LV shortening fraction: Tg-I79N 43 ± 1.2%, Tg-WT 27 ± 1.2%, non-Tg 33 ± 1.2%, $p < 0.00001$ by analysis of variance). Interestingly, at these faster heart rates, the end-diastolic dimension was significantly smaller in Tg-I79N mice (3.2 ± 0.1 mm, $p < 0.0001$ against both WT and non-Tg) than in Tg-WT mice (3.8 ± 0.1 mm) or in non-Tg mice (3.6 ± 0.2 mm). Nevertheless, Doppler indices of diastolic filling were not significantly different. Unfortunately, the A-wave could only be measured in less than 30% of the examined animals.

To exclude the possibility that the differences in LV shortening fraction were merely due to a difference in afterload, we also measured the blood pressure in anesthetized mice (Avertin). Systolic blood pressure was not significantly different (Tg-I79N mice 95 ± 4 mm Hg, $n = 10$, versus Tg-WT 89 ± 4 mm Hg, $n = 8$, $p = \text{not significant}$). Taken together, these data demonstrate that anesthetized Tg-I79N mice have increased systolic cardiac performance in vivo. A likely explanation for the difference between the systolic function in vivo and in the isolated heart is the relatively low free [Ca$^{2+}$] of mouse blood; average free [Ca$^{2+}$] measured in four nontransgenic littermates after 15 min of ketamine/xylazine anesthesia was 1.26 ± 0.03 mM, which is significantly lower than the perfusate [Ca$^{2+}$] for the base-line isolated heart recordings.

In another series of experiments, we examined whether the increased systolic function can be demonstrated in conscious Tg-I79N mice. Systolic blood pressure was not significantly different between Tg-I79N (112 ± 2 mm Hg, $n = 32$) and Tg-WT mice (114 ± 2 mm Hg, $n = 23$, $p = \text{not significant}$). Heart rate, on the other hand, was significantly lower in Tg-I79N mice (521 beats/min versus 604 beats/min, $p < 0.00001$). It remains to be determined whether the slow heart rate of Tg-I79N mice represents a vagal response to the increased cardiac contractility.

**ECG Measurements**—Cardiac arrhythmias are a potential
cause of sudden death. Limb-lead ECGs were recorded from anesthetized non-Tg, Tg-WT, and Tg-I79N mice (Fig. 4A). The most significant finding was that Tg-I79N had a consistently prolonged PR interval representing the conduction time from the atria to the ventricle. The PR prolongation was independent of the anesthetic used (data not shown) and was more pronounced in chronically exercised mice (Fig. 4B). As shown in Fig. 4C, the degree of PR prolongation appeared to be related to the expression level of the mutant TnT protein; line 8 with higher levels of Tg-I79N had more PR prolongation than line 9 with lower protein levels. Although PR prolongation is not a common ECG finding in FHC patients, left atrial enlargement is often observed. Left atrial hypertrophy in Tg-I79N mice was documented on autopsy. QRS duration and heart rate were not statistically different, but the QT interval was significantly shorter in Tg-I79N mice (line 9: 43 ± 6.0 ms, n = 8; line 8: 51 ± 6.0 ms, n = 5; Tg-WT: 67 ± 4.5 ms, n = 13; non-Tg: 67 ± 2.5 ms, n = 13, p < 0.05 between groups). Arrhythmias were not observed in Tg-I79N mice at base line.

**In Vivo Cardiac Performance under Inotropic Stimulation**—Based on the results from the isolated heart studies and the simulation studies, raising [Ca\(^{2+}\)]\(_o\) predominantly affects diastolic function (Figs. 1 and 2). To test this hypothesis in vivo, we examined the effect of raising intracellular [Ca\(^{2+}\)] via inotropic stimulation with isoproterenol, because it is difficult to raise plasma-free [Ca\(^{2+}\)]\(_o\) in vivo without causing significant toxicity. To detect abnormalities in diastolic function, ketamine/xylazine anesthesia was used for echocardiography and Doppler studies, because, based on our experience from the base-line studies, it allowed better Doppler recordings of mitral inflow compared with Avertin anesthesia. When mice were injected with 1.5 mg/kg isoproterenol, several Tg-I79N mice died shortly after injection. Therefore, echocardiography and Doppler studies were performed with a lower dose of 0.1 mg/kg isoproterenol intraperitoneally (Table II). Whereas isoproterenol produced a dramatic increase in contractility in non-TG and Tg-WT mice (LV shortening fraction increased by 26 ± 3% in Tg-WT, n = 12), Tg-I79N mice showed a smaller inotropic response (LV shortening fraction increased only by 9 ± 3% and 8 ± 3% in lines 9 and 8, n = 7 and 6, p < 0.01 against WT). In fact, four out of 13 Tg-I79N mice, but none of the 12 Tg-WT mice, later developed global LV hypokinesis and died. Doppler measurements demonstrated that this impaired inotropic response was not caused by an outflow obstruction, since both WT and I79N had similar aortic outflow velocities (see Table II). Impaired ventricular relaxation and increased diastolic chamber stiffness, as evidenced by the shorter E-wave deceleration time, loss of A-wave, and increased E/A ratio on Doppler measurements in I79N mice (Fig. 5) probably contributed to the isoproterenol-induced cardiac dysfunction.

To further investigate the isoproterenol-induced deaths of TgI79N mice, we repeated the isoproterenol experiments with continuous ECG monitoring. At the lower dose (0.1 mg/kg intraperitoneally), 75% of the examined Tg-I79N mice exhibited loss in R-wave amplitude, QRS widening, and T-wave inversion, and 25% died (Fig. 6A). Heart rate peaked 3 min after injection of isoproterenol before significant ECG changes developed in the Tg-I79N mice. Despite a similar maximal heart rate in all four groups, the significant PR prolongation in the Tg-I79N mice was consistently observed (Tg-I79N line 8, n = 5: 43 ± 3.2 ms; line 9, n = 8: 44 ± 1.6 ms; Tg-WT, n = 12: 35 ± 1.2 ms; non-Tg, n = 13: 34 ± 0.8 ms, p < 0.05 Tg-79 versus Tg-WT). QRS duration and QT interval were not statistically different between the four groups. At a higher dose of isoproterenol (1.5 mg/kg intraperitoneally), all Tg-I79N mice exhib-

---

**Photo 5.** Mitral inflow velocity measurements after low dose isoproterenol. Representative examples of two-dimensional guided Doppler recordings of mitral inflow velocity after low dose isoproterenol (0.1 mg/kg intraperitoneally). I79N mice have a faster deceleration of the E-wave (equal to early diastolic mitral inflow velocity) and decreased A-wave amplitude (equal to late diastolic mitral inflow velocity due to atrial contraction). These findings are consistent with increased diastolic ventricular chamber stiffness.

**Fig. 6.** Dose-dependence of isoproterenol-induced ECG changes and mortality. ECG changes (loss of R-wave amplitude, QRS widening, T-wave inversion) and mortality were quantified at a low dose (0.1 mg/kg intraperitoneally (A)) and a high dose (1.5 mg/kg intraperitoneally (B)) of isoproterenol by intraperitoneal injection. The effect of isoproterenol on ECG and mortality was dose-dependent.
FIG. 7. Heart rate response and ECG changes after isoproterenol. Representative heart rate response and ECG morphology after intraperitoneal injection of isoproterenol (1.5 mg/kg). The insets illustrate the changes in ECG morphology over time. Compared with Tg-WT mice (upper panel), Tg-I79N mice (lower panel) develop a rapid increase, followed by a progressive decrease in heart rate, which is accompanied by characteristic changes in ECG morphology (loss of R-wave, QRS widening, and T-wave inversion, insets of D). Tg-I79N mice then die from progressive conduction blocks (PR prolongation and second and third degree atrioventricular block (AVB), insets of E–G).
ited loss in R-wave amplitude, QRS widening, and T-wave inversion, and 75% of the animals died within 20 min of injection (Fig. 6B). Compared with the sustained acceleration in heart rate of Tg-WT mice, the same isoproterenol injection resulted only in a very transient increase in heart rate in Tg-I79N mice, followed by progressive conduction blocks and eventually death (Fig. 7). The insets in Fig. 7 illustrate the profound changes in QRS morphology (progressive loss in R-wave amplitude, QRS widening, and T-wave inversion) that developed after isoproterenol injection. Ventricular tachyarrhythmias were observed only in a few mice and were never sustained more than a few seconds. Tg-I79N mice died with progressive conduction blocks present on ECG. Autopsy examination demonstrated dilated atria with pulmonary and hepatic congestion and no evidence for bleeding. Taken together, these data indicate that the isoproterenol-induced deaths were not caused by ventricular tachyarrhythmias.

**Effect of Chronic Exercise**—Eight Tg-WT, eight Tg-I79N, and eight non-Tg mice underwent 4 weeks of chronic swimming exercise. Two deaths occurred, one each in the Tg-WT and the Tg-I79N group. No apparent difference in exercise tolerance was observed between the groups. Except for the increase in PR interval in Tg-I79N mice (Fig. 4B), there were no other ECG abnormalities or arrhythmias found in ECG studies obtained after the completion of the exercise program.

**Histopathology of Tg Mice**

Hearts of Tg-I79N were smaller than age- and sex-matched Tg-WT and non-Tg mice, with a significantly decreased heart weight/body weight ratio, as already reported in the preceding article (7). However, we found evidence for left atrial hypertrophy (left atrial weight Tg-I79N, line 9: 10 ± 2 mg versus Tg-WT: 5 ± 1 mg, n = 6 each, p = 0.08), which was significantly different when the values were corrected for the lower ventricular weight of Tg-I79N mice (left atrial weight/heart weight ratio Tg-I79N: 0.048 ± 0.009 versus Tg-WT: 0.023 ± 0.003, n = 6 each, p = 0.025). Histological examinations of hematoxylin and eosin (H+E)-stained ventricular sections from non-Tg, Tg-WT (line 3), and Tg-I79N (line 9) revealed normal myocyte architecture and no major differences between the three lines (Fig. 8, upper panels). Tg-WT (line 3) and Tg-I79N (line 9) may have somewhat more nuclear pleomorphism (greater variation in the size and appearance of the nuclei) than the non-Tg mice. On trichrome (TRIC)-stained sections, where muscle and red blood cells are stained red and areas containing fibrosis or collagen are stained blue, no differences between the three lines were observed. Chronic exercise had no effect on cardiac histology in either group.

**DISCUSSION**

The major finding of this study is that significant alterations in cardiac contractile and electrical properties occur in transgenic mice carrying the TnT-I79N mutation. In the isolated heart, the effect of the I79N mutation on cardiac performance depended on the Ca\(^{2+}\) concentration of the perfusate; systolic function was significantly increased in Tg-I79N hearts only at
Cardiac Dysfunction of TnT (I79N) Transgenic Mice

0.5 and 1 mmol/liter [Ca\(^{2+}\)]_o with no difference in diastolic function. At higher [Ca\(^{2+}\)]_o, diastolic dysfunction became manifest as both an increase in end-diastolic pressure and in time to 90% relaxation (Table I and Figs. 1 and 2). In vivo measurements with echocardiography and Doppler confirmed that, at base-line, systolic function was significantly higher in Tg-I79N mice without evidence for diastolic dysfunction (Table II and Fig. 3). However, inotropic stimulation with isoproterenol resulted only in a modest initial contractile response but later caused significant mortality only in Tg-I79N mice (Fig. 6). Doppler studies ruled out aortic outflow obstruction and were consistent with impaired diastolic filling (Table II and Fig. 5). Continuous ECG monitoring ruled out ventricular tachyarrhythmias as a cause of death and showed changes in ECG morphology and bradycardia (Fig. 7). Morphological and histological studies ruled out significant ventricular hypertrophy, fibrosis, or myocyte disarray (Fig. 8). Our results are consistent with the hypothesis that the increased myofilament Ca\(^{2+}\) sensitivity due to the I79N mutation enhances base-line contractility but leads to cardiac dysfunction under inotropic stimulation. This mechanism may contribute to excess mortality during exercise or other states with high levels of endogenous catecholamines, even in the absence of significant cardiac hypertrophy.

**Cardiac Performance of Tg-I79N Mice**—In the isolated heart of I79N mice, systolic function was higher, and relaxation was impaired. Although no data from humans or other transgenic models carrying the I79N mutation exist, similar findings have been reported in a mouse model expressing the FHC-linked TnT-R92Q mutation (17–19), whereas impaired systolic function has been reported in an independently created transgenic mouse model of the same mutations (22). Data presented here may provide explanation for the disparate results; at low [Ca\(^{2+}\)]_o, the positive inotropic effect of the leftward shift in Ca\(^{2+}\) sensitivity of skinned fibers predominates (Fig. 2A). At higher [Ca\(^{2+}\)]_o or during inotropic stimulation, peak intracellular [Ca\(^{2+}\)] may reach levels closer to the flat portion of the calcium-force relationship in 179N mice, and little additional force is produced. Under those conditions, the impaired relaxation due to the increased myofilament Ca\(^{2+}\) sensitivity predominates. Thus, the measured cardiac performance depends critically on the inotropic state of the preparation and may differ depending on the experimental conditions.

What other factors besides the level of free Ca\(^{2+}\) could have contributed to the difference in systolic function measured under base-line conditions (i.e., increased in vivo, but no difference in the isolated heart)? One explanation is that end-diastolic pressure was set at 8 mm Hg for the isolated heart measurements. This experimental strategy allows one to compare contractile performance of hearts of different sizes but underestimates developed pressure when diastolic compliance is impaired (31). However, the lower LV balloon volume of 179N hearts would also be consistent with a decreased diastolic compliance. Thus, if diastolic compliance was impaired in the 179N hearts at a perfusate [Ca\(^{2+}\)]_o of 2 mm, their systolic performance may actually have been underestimated in our isolated heart experiments.

Contractile indices obtained by echocardiography are significantly influenced by changes in preload and afterload. There are several reasons to believe that the reported in vivo results represent true differences in myocardial systolic performance; afterload, as estimated by systolic blood pressure, was not significantly different between Tg-I79N and Tg-WT. Although we did not directly measure the end-diastolic pressure (preload) in vivo, the end-diastolic LV dimensions can be used as a correlate if heart rate and diastolic compliance are the same. End-diastolic LV dimensions were significantly smaller in the Tg-I79N mice, suggesting that either EDP was lower, or compliance was decreased in Tg-I79N mice. Thus, changes in preload are unlikely to be the explanation for the profound increase of the shortening fraction in the 179N mice.

In the Tg-I79N mice, ventricular relaxation was predicted to be slowed under basal conditions, based on our simulation studies and at a [Ca\(^{2+}\)]_o of 2 mm or above based on the isolated heart studies (Table I). Yet, we did not find evidence for impaired filling on Doppler under base-line conditions. One possibility is that the Doppler technique is not sensitive enough to detect subtle increases in diastolic chamber stiffness. Another possible explanation is the relatively low free [Ca\(^{2+}\)]_o (1.25 mm) in mouse blood. In the isolated heart experiments, diastolic relaxation times were not significantly different at [Ca\(^{2+}\)]_o of 0.5 or 1 mm, and EDP was significantly higher in the Tg-WT compared with Tg-I79N hearts (Fig. 2B). This increase of EDP at low [Ca\(^{2+}\)]_o is somewhat surprising but has been observed previously in the isolated heart preparation and is thought to be related to the turgor effect, when the perfusion pressure exceeds the systolic pressure during continuous retrograde perfusion (18).

**Cardiac Electrophysiology and Arrhythmias**—Unlike in the MHC403+/− mouse model of FHC (23), ventricular arrhythmias were not observed in sedentary or exercised 179N mice at base line. However, this may not be expected during the short period of ECG recordings employed in our study, since even in FHC patients ventricular arrhythmias are relatively rare and occur on average less than once per month (6).

Surprisingly, transgenic mice expressing TnT-I79N had a consistently prolonged PR interval on ECG recordings. The PR prolongation was independent of the anesthetic used, was correlated to gene dosage (Fig. 4C), and was more pronounced in chronically exercised mice (Fig. 4B). The duration of the PR interval is determined by conduction from the atria to the ventricle and is controlled by the autonomic nervous system. An increase in vagal tone therefore could account for the PR prolongation and could represent a reflex mechanism to increased cardiac contractility of 179N mice (e.g., via the baroreceptor reflex). The slower heart rate of conscious I79N mice is consistent with this hypothesis. Alternatively, atrial hypertrophy has been associated with PR prolongation in other mouse models of cardiac hypertrophy (10). We found significant atrial hypertrophy in 179N mice, and this may have contributed to the PR prolongation. The atrial hypertrophy could result from atrial I79N overexpression driven by the MHC promoter, which occurs earlier in the atria than in the ventricle (24), or might be a compensatory response to impaired diastolic relaxation of the ventricle, or both. Atrial hypertrophy has also been described in mice expressing the TnT-R92Q mutation (17).

**Isoproterenol-induced Contractile Abnormalities, ECG Changes, and Mortality**—Based on our echocardiography and Doppler measurements, isoproterenol had little effect on systolic indices but resulted in significantly altered measurements of diastolic filling in Tg-I79N mice. Although other factors such as pulmonary vein flow, end-diastolic pressure, and atrial compliance can contribute to the shape of Doppler signals during mitral inflow, Doppler indices can be used to detect diastolic dysfunction; Little et al. (25) have shown that in particular the E-wave deceleration time is well correlated with diastolic chamber stiffness independently of preload. Accordingly, changes in this parameter could detect even the transient increase of diastolic chamber stiffness that occurs after coronary artery bypass surgery (26, 27). Together with the data from the isolated heart and the modeling studies, the significantly shortened E-wave deceleration time (Table II and Fig. 5)
Cardiac Dysfunction of TnT (I79N) Transgenic Mice

in both transgenic lines suggests that isoproterenol induced an increased diastolic chamber stiffness in Tg-I79N mice. Obviously, an extensive cardiac catheterization study will have to confirm these observations in the future.

One surprising finding was the high mortality of Tg-I79N mice following the isoproterenol injection. Based on our echocardiography and Doppler findings, the deaths were not caused by an aortic outflow obstruction, which is a common cause of death in end-stage human FHC (28). Deaths were also not due to ventricular tachyarrhythmias, another major cause of death in FHC patients (6), or hemorrhage. Rather, Tg-I79N mice died after isoproterenol induced changes in ECG morphology (loss of R-wave, ST segment depression, and T-wave inversion) and heart block (Fig. 6). Although not diagnostic, similar ECG abnormalities can be observed with acute cardiac ischemia. Myocardial ischemia could be detected in all FHC patients that survived a cardiac arrest (29) and could play a role in the isoproterenol-induced mortality of Tg-I79N mice.

Several lines of evidence suggest that autonomic dysregulation could have contributed to the isoproterenol induced mortality as follows. (i) Tg-I79N shows evidence of an increase in vagal output (lower basal heart rate, PR prolongation). (ii) Deaths occurred due to bradycardia and heart block. (iii) Isoproterenol challenge can be used to induce vasovagal syncope in humans. (iv) In FHC patients, autonomic dysfunction can cause an inappropriate decrease in systemic vascular resistance at high work loads (30) and has been reported in a patient carrying a TnT mutation (4). Somewhat against this hypothesis is the lower maximal force of the force/pCa relationship. Thus, the lower maximal force per cross-sectional area previously reported (7) might decrease the contractile reserve available to increase cardiac output appropriately in response to isoproterenol-induced vasodilatation. (iv) The isoproterenol response may activate ventricular mechanoreceptors and thereby cause chronic alterations in vagal tone, which could contribute to bradycardia and death in response to isoproterenol. In summary, Tg-I79N mice may become a valuable model to explore potential mechanisms of sudden death induced by the TnT-I79N mutation.

Acknowledgments—We are very grateful for the help of Dr. Carl Apstein, who taught us the technique of isovolumic contractility measurements in the isolated mouse heart.

REFERENCES

1. Watkins, H., McMenna, W. J., Thierfelder, L., Suk, H. J., Anan, R., O'Donoghue, A., Spirito, P., Matsutomi, A., Moravec, C. S., Seidman, J. G., and Seidman, C. E. (1995) N. Engl. J. Med. 332, 1058–1064

2. Watkins, H., Seidman, C. E., Seidman, J. G., Feng, H. S., and Sweeney, H. L. (1996) J. Clin. Invest. 98, 2456–2461

3. Mulvany, J. C., Corfield, V. A., Posen, B., Nguemba, K., Seidman, C., Brink, P. A., and Watkins, H. (1997) J. Am. Coll. Cardiol. 29, 549–555

4. Varnava, A., Baboonian, G., Davison, F., de Cruz, L., Elliott, P. M., Davies, M., and McKenna, W. J. (1999) Heart 82, 621–624

5. Ho, C. Y., Lever, H. M., DeSanctis, R., Farver, C. F., Seidman, J. G., and Seidman, C. E. (2000) Circulation 101, 1950–1955

6. Maron, B. J., Shippy, W. K., Link, M. S., Epstein, A. E., Arequist, A. K., Daubert, J. P., Bardy, G. H., Favalre, S., Rea, R. F., Boriani, G., Estes, N. A., III, and For Mos, P. (2000) N. Engl. J. Med. 342, 365–373

7. Miller, T., Szczesna, D., Housmans, P. R., Zhao, J., deFreitas, F., Gomes, A. V., Culbreth, L., McCue, J., Wang, Y., Xu, Y., Kerrick, W. G., and Potter, J. D. (2001) J. Biol. Chem. 276, 3743–3755

8. Lim, C. C., Liao, B., Varma, N., and Apstein, C. S. (1999) Am. J. Physiol. 277, H2083–H2090

9. Fabiato, A. (1988) Methods Enzymol. 157, 378–417

10. Knollmann, B. C., Knollmann-Ritschel, B. E. C., Weissman, N. J., Jones, L. R., and Morad, M. (2000) J. Physiol. 525, 483–498

11. Mitchell, G. F., Jaron, A., and Koren, G. (1998) Am. J. Physiol. 274, H747–H751

12. Hoit, B. D., Khoury, S. F., Kranias, E. G., Ball, N., and Walsh, R. A. (1995) Circ. Res. 77, 632–637

13. Geisterfer-Lowrance, A. A., Christe, M., Conner, D. A., Ingwall, J. S., Schoen, C., and Apstein, C. S. (1996) J. Biol. Chem. 271, 231–234

14. Robertson, S. P., Johnson, J. D., and Potter, J. D. (1991) J. Biol. Chem. 266, 559–569

15. Mikane, T., Araki, J., Kohno, K., Nakayama, Y., Suzuki, S., Shinuma, S., Matsubara, H., Hirakawa, M., Takaki, M., and Suga, H. (1997) Am. J. Physiol. 273, H2891–H2897

16. Landesberg, A., and Sideman, S. (1997) Am. J. Physiol. 276, H1100–H1101

17. Tardiff, J. C., Hewett, T. E., Palmer, B. M., Olsson, C., Factor, S. M., Moore, R. L., Robbins, J., and Leibowitz, I. A. (1999) J. Clin. Invest. 104, 469–481

18. Spindler, M., Saus, R. W., Christe, M. E., Sweeney, H. L., Seidman, C. E., Seidman, J. G., and Ingwall, J. S. (1998) J. Clin. Invest. 101, 1775–1783

19. Georgakopoulos, D., Christe, M. E., Giewat, M., Seidman, C. E., Seidman, C. M., Seidman, J. G., and Kaas, D. A. (1999) Nat. Med. 5, 327–330

20. Apstein, C. S., Deckelbaum, L., Hapogian, L., and Hood, W. B., Jr. (1978) Am. J. Physiol. 235, H637–H648

21. Christensen, G., Wang, Y., and Chien, K. R. (1997) J. Am. Coll. Cardiol. 30, 365–374

22. Berul, C. I., Christe, M. E., Arowowitz, M. J., Seidman, C. E., Seidman, J. G., and Mendelsohn, M. E. (1997) J. Clin. Invest. 99, 570–576

23. Subramanian, A., Jones, W. K., Golez, I., Wert, S., Neumann, J., and Robbins, J. (1991) J. Biol. Chem. 266, 24613–24620

24. Little, W. C., Ohno, M., Kitzman, D. W., Thomas, J. D., and Cheng, C. P. (1995) Circulation 92, 1933–1939

25. Robertson, P. A., Apstein, C. S., Mendes, L. A., Connelly, G. P., Aldea, G. S., Sheinman, R. J., and Davidoff, R. (1999) J. Am. Coll. Cardiol. 34, 914–918

26. McKenney, P. A., Apstein, C. S., Mendes, L. A., Connelly, G. P., Aldea, G. S., Sheinman, R. J., and Davidoff, R. (1994) J. Am. Coll. Cardiol. 24, 1189–1194

27. Wight, E. D., Rakowski, H., Kimball, B. F., and Williams, W. G. (1995) Circulation 92, 1680–1692

28. Wiks, V., Bonov, B. O., Epstein, S. E., and Fannanapazaz, L. (1993) J. Am. Coll. Cardiol. 22, 796–804

29. Prasad, K., and Frenneaux, M. P. (1998) Heart 79, 538–540

30. Stromer, H., Cittadini, A., Szymanska, G., Apstein, C. S., and Morgan, J. P. (1997) Am. J. Physiol. 275, H501–H510